Pharmacogenomics: a reality or still a promise?
- PMID: 17064812
- PMCID: PMC1759823
- DOI: 10.1016/j.lungcan.2006.09.014
Pharmacogenomics: a reality or still a promise?
Abstract
Although notable progress has been made in the treatment of non-small-cell lung cancer (NSCLC) in recent years, this disease is still associated with a poor prognosis for most patients. Modern techniques have facilitated the identification of specific genetic factors that may play a role in disease progression and patient response to therapy, prompting research efforts to identify the clinical predictors of outcome for NSCLC. Recent evidence suggests that the application of a pharmacogenomic approach has the potential to greatly improve survival in certain subpopulations of patients with NSCLC, which could profoundly influence the decision-making process used in evolving treatment strategies for this malignancy.
Figures
Similar articles
-
[Clinical significance of ERCC1, RRM1 and TS in non-small cell lung cancer].Zhongguo Fei Ai Za Zhi. 2014 Jun 20;17(6):496-500. doi: 10.3779/j.issn.1009-3419.2014.06.11. Zhongguo Fei Ai Za Zhi. 2014. PMID: 24949692 Free PMC article. Review. Chinese. No abstract available.
-
DNA repair and survival in lung cancer--the two faces of Janus.N Engl J Med. 2007 Feb 22;356(8):771-3. doi: 10.1056/NEJMp068308. N Engl J Med. 2007. PMID: 17314336 No abstract available.
-
Phase II pharmacogenomics-based adjuvant therapy trial in patients with non-small-cell lung cancer: Southwest Oncology Group Trial 0720.Clin Lung Cancer. 2007 Sep;8(8):509-11. doi: 10.3816/CLC.2007.n.039. Clin Lung Cancer. 2007. PMID: 17948610 Clinical Trial. No abstract available.
-
Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.Expert Rev Mol Diagn. 2007 May;7(3):261-8. doi: 10.1586/14737159.7.3.261. Expert Rev Mol Diagn. 2007. PMID: 17489733 Review.
-
[Biomarkers - the way towards individualized chemotherapy in non-small cell lung cancer (NSCLC)].Wien Med Wochenschr. 2007;157(21-22):554-61. doi: 10.1007/s10354-007-0483-x. Wien Med Wochenschr. 2007. PMID: 18157593 Review. German.
Cited by
-
Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer.J Thorac Oncol. 2010 Apr;5(4):484-90. doi: 10.1097/JTO.0b013e3181ccb27b. J Thorac Oncol. 2010. PMID: 20107425 Free PMC article.
References
-
- Bepler G, Gautam A, McIntyre LM, Beck AF, Chervinsky DS, et al. Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J Clin Oncol. 2002;20:1353–1360. - PubMed
-
- Pitterle DM, Jolicoeur EC, Bepler G. Hot spots for molecular genetic alterations in lung cancer. In Vivo. 1998;12:643–658. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical